{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T19:23:55Z","timestamp":1766690635600,"version":"3.44.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jns.2020.117204","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T22:32:10Z","timestamp":1603319530000},"page":"117204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in M\u00e9xico"],"prefix":"10.1016","volume":"419","author":[{"given":"Adriana","family":"Casallas-Vanegas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Gomez-Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adib Jorge","family":"de Sar\u00e1chaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indhira","family":"Zabala-Angeles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Garc\u00eda-Estrada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge C.","family":"Salado-Burbano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Clara","family":"DiazGranados-Palacio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresita","family":"Corona-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"de Jes\u00fas Flores-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Rivas-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jns.2020.117204_bb0005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"Weinshenker","year":"2017","journal-title":"Mayo Clin. Proc."},{"issue":"1\u20132","key":"10.1016\/j.jns.2020.117204_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jns.2011.01.002","article-title":"Neuromyelitis optica: an update","volume":"303","author":"Mat\u00e0","year":"2011","journal-title":"J. Neurol. Sci. [Internet]"},{"issue":"4","key":"10.1016\/j.jns.2020.117204_bb0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord. [Internet]."},{"issue":"8","key":"10.1016\/j.jns.2020.117204_bb0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.jns.2020.117204_bb0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","article-title":"Neurodegeneration in multiple sclerosis and neuromyelitis optica","volume":"88","author":"Kawachi","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry [Internet]."},{"issue":"2","key":"10.1016\/j.jns.2020.117204_bb0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol. [Internet]"},{"key":"10.1016\/j.jns.2020.117204_bb0035","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"370","author":"Xu","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.jns.2020.117204_bb0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2015.02.012","article-title":"Analysis of the treatment of neuromyelitis optica","volume":"351","author":"Torres","year":"2015","journal-title":"J. Neurol. Sci. [Internet]"},{"key":"10.1016\/j.jns.2020.117204_bb0045","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10206","key":"10.1016\/j.jns.2020.117204_bb0050","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jns.2020.117204_bb0055","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4\u2013positive Neuromyelitis Optica Spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med. [Internet]."},{"issue":"15","key":"10.1016\/j.jns.2020.117204_bb0060","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2020.117204_bb0065","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J. Immunol. [Internet]."},{"key":"10.1016\/j.jns.2020.117204_bb0070","series-title":"B Cell Trophic Factors and B Cell Antagonism in Autoimmune Disease [Internet]","first-page":"140","article-title":"The biology of CD20 and its potential as a target for mAb therapy","author":"Cragg","year":"2004"},{"issue":"1","key":"10.1016\/j.jns.2020.117204_bb0075","first-page":"18","article-title":"Efficacy and safety of rituximab in neuromyelitis optica: review of evidence","volume":"22","author":"Etemadifar","year":"2017","journal-title":"J. Res. Med. Sci. [Internet]"},{"issue":"1","key":"10.1016\/j.jns.2020.117204_bb0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol. [Internet]"},{"issue":"15","key":"10.1016\/j.jns.2020.117204_bb0085","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.jns.2020.117204_bb0090","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2020.117204_bb0095","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2020.117204_bb0100","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neurol.2017.11.005","article-title":"Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders","volume":"174","author":"Ciron","year":"2018","journal-title":"Rev. Neurol. (Paris)"},{"issue":"2","key":"10.1016\/j.jns.2020.117204_bb0105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.jns.2020.117204_bb0110","first-page":"1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurol. Int."},{"key":"10.1016\/j.jns.2020.117204_bb0115","series-title":"In: Current Clinical Neurology","article-title":"Neuromyelitis optica spectrum disorders","author":"Cahill","year":"2020"},{"issue":"11","key":"10.1016\/j.jns.2020.117204_bb0120","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol. [Internet]"},{"issue":"3","key":"10.1016\/j.jns.2020.117204_bb0125","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/WCO.0000000000000455","article-title":"Neuromyelitis optica and neuromyelitis optica spectrum disorders","volume":"30","author":"Marignier","year":"2017","journal-title":"Curr. Opin. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2020.117204_bb0130","first-page":"1270","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurol. Int."},{"issue":"11","key":"10.1016\/j.jns.2020.117204_bb0135","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","volume":"65","author":"Treatment of Neuromyelitis Optica With Rituximab","year":"2008","journal-title":"Arch. Neurol. [Internet]"},{"issue":"15","key":"10.1016\/j.jns.2020.117204_bb0140","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jns.2020.117204_bb0145","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/1352458511404586","article-title":"Impact of rituximab on relapse rate and disability in neuromyelitis optica","volume":"17","author":"Bedi","year":"2011","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2020.117204_bb0150","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jns.2016.11.016","article-title":"Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up","volume":"372","author":"Evangelopoulos","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"8","key":"10.1016\/j.jns.2020.117204_bb0155","first-page":"710","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurol. Int."},{"issue":"4","key":"10.1016\/j.jns.2020.117204_bb0160","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.msard.2013.10.003","article-title":"Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica","volume":"3","author":"Graves","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.jns.2020.117204_bb0165","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol. [Internet]"},{"issue":"3","key":"10.1016\/j.jns.2020.117204_bb0170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/1756285616632653","article-title":"An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica","volume":"9","author":"Collongues","year":"2016","journal-title":"Ther. Adv. Neurol. Disord. [Internet]."},{"issue":"4","key":"10.1016\/j.jns.2020.117204_bb0175","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult. Scler. J."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20305402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20305402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:54:21Z","timestamp":1758383661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20305402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":35,"alternative-id":["S0022510X20305402"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.117204","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in M\u00e9xico","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.117204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117204"}}